241 related articles for article (PubMed ID: 23951137)
1. Xanthine oxidase mediates axonal and myelin loss in a murine model of multiple sclerosis.
Honorat JA; Kinoshita M; Okuno T; Takata K; Koda T; Tada S; Shirakura T; Fujimura H; Mochizuki H; Sakoda S; Nakatsuji Y
PLoS One; 2013; 8(8):e71329. PubMed ID: 23951137
[TBL] [Abstract][Full Text] [Related]
2. Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
Nomura J; Busso N; Ives A; Tsujimoto S; Tamura M; So A; Yamanaka Y
PLoS One; 2013; 8(9):e75527. PubMed ID: 24086554
[TBL] [Abstract][Full Text] [Related]
3. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.
Nomura J; Busso N; Ives A; Matsui C; Tsujimoto S; Shirakura T; Tamura M; Kobayashi T; So A; Yamanaka Y
Sci Rep; 2014 Apr; 4():4554. PubMed ID: 24686534
[TBL] [Abstract][Full Text] [Related]
4. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Forte M; Gold BG; Marracci G; Chaudhary P; Basso E; Johnsen D; Yu X; Fowlkes J; Rahder M; Stem K; Bernardi P; Bourdette D
Proc Natl Acad Sci U S A; 2007 May; 104(18):7558-63. PubMed ID: 17463082
[TBL] [Abstract][Full Text] [Related]
5. Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Sabán-Ruiz J; Alonso-Pacho A; Fabregate-Fuente M; de la Puerta González-Quevedo C
Antiinflamm Antiallergy Agents Med Chem; 2013; 12(1):94-9. PubMed ID: 23286293
[TBL] [Abstract][Full Text] [Related]
6. Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration.
van Strien ME; de Vries HE; Chrobok NL; Bol JGJM; Breve JJP; van der Pol SMP; Kooij G; van Buul JD; Karpuj M; Steinman L; Wilhelmus MM; Sestito C; Drukarch B; Van Dam AM
Brain Behav Immun; 2015 Nov; 50():141-154. PubMed ID: 26133787
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat ameliorates secondary progressive experimental autoimmune encephalomyelitis by restoring mitochondrial energy production in a GOT2-dependent manner.
Honorat JA; Nakatsuji Y; Shimizu M; Kinoshita M; Sumi-Akamaru H; Sasaki T; Takata K; Koda T; Namba A; Yamashita K; Sanda E; Sakaguchi M; Kumanogoh A; Shirakura T; Tamura M; Sakoda S; Mochizuki H; Okuno T
PLoS One; 2017; 12(11):e0187215. PubMed ID: 29107957
[TBL] [Abstract][Full Text] [Related]
8. Pathological findings in rats with experimental allergic encephalomyelitis.
Dong M; Liu R; Guo L; Li C; Tan G
APMIS; 2008 Nov; 116(11):972-84. PubMed ID: 19132994
[TBL] [Abstract][Full Text] [Related]
9. Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
Prinz J; Karacivi A; Stormanns ER; Recks MS; Kuerten S
PLoS One; 2015; 10(12):e0144847. PubMed ID: 26658811
[TBL] [Abstract][Full Text] [Related]
10. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis.
Gold BG; Voda J; Yu X; McKeon G; Bourdette DN
J Neurosci Res; 2004 Aug; 77(3):367-77. PubMed ID: 15248293
[TBL] [Abstract][Full Text] [Related]
11. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.
Wen J; Ribeiro R; Tanaka M; Zhang Y
Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
Malik UZ; Hundley NJ; Romero G; Radi R; Freeman BA; Tarpey MM; Kelley EE
Free Radic Biol Med; 2011 Jul; 51(1):179-84. PubMed ID: 21554948
[TBL] [Abstract][Full Text] [Related]
13. Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination.
Choi EY; Lim JH; Neuwirth A; Economopoulou M; Chatzigeorgiou A; Chung KJ; Bittner S; Lee SH; Langer H; Samus M; Kim H; Cho GS; Ziemssen T; Bdeir K; Chavakis E; Koh JY; Boon L; Hosur K; Bornstein SR; Meuth SG; Hajishengallis G; Chavakis T
Mol Psychiatry; 2015 Jul; 20(7):880-888. PubMed ID: 25385367
[TBL] [Abstract][Full Text] [Related]
14. Abnormal morphology of myelin and axon pathology in murine models of multiple sclerosis.
Bando Y; Nomura T; Bochimoto H; Murakami K; Tanaka T; Watanabe T; Yoshida S
Neurochem Int; 2015 Feb; 81():16-27. PubMed ID: 25595039
[TBL] [Abstract][Full Text] [Related]
15. 2-BFI attenuates experimental autoimmune encephalomyelitis-induced spinal cord injury with enhanced B-CK, CaATPase, but reduced calpain activity.
Wang P; Wang ZW; Lin FH; Han Z; Hou ST; Zheng RY
Biochem Biophys Res Commun; 2011 Mar; 406(1):152-7. PubMed ID: 21303658
[TBL] [Abstract][Full Text] [Related]
16. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Berard JL; Wolak K; Fournier S; David S
Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance.
Nambu H; Takada S; Maekawa S; Matsumoto J; Kakutani N; Furihata T; Shirakawa R; Katayama T; Nakajima T; Yamanashi K; Obata Y; Nakano I; Tsuda M; Saito A; Fukushima A; Yokota T; Nio-Kobayashi J; Yasui H; Higashikawa K; Kuge Y; Anzai T; Sabe H; Kinugawa S
Cardiovasc Res; 2021 Feb; 117(3):805-819. PubMed ID: 32402072
[TBL] [Abstract][Full Text] [Related]
18. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis.
Hammer LA; Zagon IS; McLaughlin PJ
Brain Res Bull; 2015 Mar; 112():42-51. PubMed ID: 25647234
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Tsuda H; Kawada N; Kaimori JY; Kitamura H; Moriyama T; Rakugi H; Takahara S; Isaka Y
Biochem Biophys Res Commun; 2012 Oct; 427(2):266-72. PubMed ID: 22995295
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis.
Wen J; Ariyannur PS; Ribeiro R; Tanaka M; Moffett JR; Kirmani BF; Namboodiri AM; Zhang Y
J Neuroimmune Pharmacol; 2016 Dec; 11(4):763-773. PubMed ID: 27562847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
